XMAB808

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

XMAB808 is an experimental drug currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being investigated in combination with pembrolizumab, an immunotherapy drug. The goal of these early-phase trials (Phase 1) is primarily to determine the safety and tolerability of XMAB808 when given with pembrolizumab, and to find the best dose to use in future studies. These trials are not designed to see if the drug combination works better than standard treatments, but rather to assess safety and determine appropriate dosages for further investigation. XMAB808 is not yet approved for treating colorectal cancer or any other condition.

Mechanism of Action

XMAB808 is a bispecific antibody. It is designed to target two different proteins simultaneously. In the context of this trial, it is being studied in combination with pembrolizumab. The specific proteins targeted by XMAB808 and its exact mechanism of action are being characterized in clinical trials. The combination aims to leverage the effects of both drugs to potentially enhance the body's immune response against cancer cells.

Side Effects

Because XMAB808 is an experimental drug in early-phase trials The full range of potential side effects is still being evaluated. The primary focus of the Phase 1 trial (NCT05585034) is to assess the safety and tolerability of XMAB808 in combination with pembrolizumab. Common side effects associated with pembrolizumab (an immunotherapy) can include fatigue Rash Diarrhea Cough Nausea Decreased appetite Vomiting Constipation Abdominal pain And musculoskeletal pain. Side effects specific to XMAB808 or the combination are being closely monitored in the trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05585034 Phase 1
Completed
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.